Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CTX TSE:HEXO TSE:LABS NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXCrescita TherapeuticsC$0.76C$0.66C$0.40▼C$0.76C$14.15M-1.33963446,005 shs20,953 shsHEXOHEXOC$0.00C$0.85▼C$4.97C$38.72M2.13253,024 shs72,643 shsLABSMediPharm LabsC$0.09C$0.07C$0.06▼C$0.11C$36.11M-0.383492250,588 shs79,252 shsVIRVir Biotechnology$10.01-1.7%$9.56$4.16▼$11.66$1.64B1.71.76 million shs1.04 million shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXCrescita Therapeutics0.00%+1.33%+2.70%+55.10%+31.03%HEXOHEXO0.00%0.00%0.00%0.00%0.00%LABSMediPharm Labs0.00%+20.00%+38.46%+28.57%+5.88%VIRVir Biotechnology0.00%-6.02%+10.38%+30.21%+62.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXCrescita TherapeuticsC$0.76C$0.66C$0.40▼C$0.76C$14.15M-1.33963446,005 shs20,953 shsHEXOHEXOC$0.00C$0.85▼C$4.97C$38.72M2.13253,024 shs72,643 shsLABSMediPharm LabsC$0.09C$0.07C$0.06▼C$0.11C$36.11M-0.383492250,588 shs79,252 shsVIRVir Biotechnology$10.01-1.7%$9.56$4.16▼$11.66$1.64B1.71.76 million shs1.04 million shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXCrescita Therapeutics0.00%+1.33%+2.70%+55.10%+31.03%HEXOHEXO0.00%0.00%0.00%0.00%0.00%LABSMediPharm Labs0.00%+20.00%+38.46%+28.57%+5.88%VIRVir Biotechnology0.00%-6.02%+10.38%+30.21%+62.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXCrescita Therapeutics 0.00N/AN/AN/AHEXOHEXO 0.00N/AN/AN/ALABSMediPharm Labs 0.00N/AN/AN/AVIRVir Biotechnology 2.89Moderate Buy$20.38103.55% UpsideCurrent Analyst Ratings BreakdownLatest CTX, HEXO, LABS, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2026VIRVir Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/4/2026VIRVir Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.002/26/2026VIRVir Biotechnology Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$20.002/24/2026VIRVir Biotechnology BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$26.00 ➝ $30.002/24/2026VIRVir Biotechnology EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$18.002/24/2026VIRVir Biotechnology Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$20.00 ➝ $24.002/24/2026VIRVir Biotechnology Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$19.002/24/2026VIRVir Biotechnology Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $18.002/17/2026VIRVir Biotechnology BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.002/9/2026VIRVir Biotechnology Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXCrescita TherapeuticsC$21.12M0.67C$0.63 per share1.20C$0.84 per share0.91HEXOHEXOC$124.10M0.00N/A1.55C$3.24 per share0.00LABSMediPharm LabsC$45.12M0.80C$0.07 per share1.30C$0.09 per share1.00VIRVir Biotechnology$68.56M23.54N/AN/A$5.50 per share1.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXCrescita Therapeutics-C$2.61MN/A37.50N/AN/A-0.44%-0.59%-8.26%N/AHEXOHEXO-C$273.18M-C$3.41N/AN/A-220.13%-106.39%-14.96%N/ALABSMediPharm Labs-C$12.05M-C$0.02N/AN/AN/A-18.32%-21.10%-7.17%N/AVIRVir Biotechnology-$437.99M-$3.16N/AN/AN/A-638.88%-49.31%-38.74%5/6/2026 (Estimated)Latest CTX, HEXO, LABS, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026VIRVir Biotechnology-$0.01N/AN/AN/A$55.49 millionN/A3/31/2026Q4 2025CTXCrescita TherapeuticsN/A-C$0.04N/A-C$0.04N/AC$5.96 million2/23/2026Q4 2025VIRVir Biotechnology-$0.42-$0.31+$0.11-$0.31$19.91 million$64.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTXCrescita TherapeuticsN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/ALABSMediPharm LabsN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXCrescita Therapeutics2.143.332.29HEXOHEXO125.990.410.40LABSMediPharm Labs0.562.773.10VIRVir BiotechnologyN/A5.545.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXCrescita Therapeutics3.14%HEXOHEXO7.57%LABSMediPharm Labs0.34%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipCTXCrescita Therapeutics10.87%HEXOHEXO3.03%LABSMediPharm Labs4.45%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXCrescita Therapeutics6218.61 millionN/ANot OptionableHEXOHEXO69044.00 millionN/ANot OptionableLABSMediPharm Labs130424.86 millionN/ANot OptionableVIRVir Biotechnology580161.23 million135.44 millionOptionableCTX, HEXO, LABS, and VIR HeadlinesRecent News About These CompaniesVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare ConferenceMay 5 at 4:05 PM | businesswire.comVir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares of StockMay 5 at 4:57 AM | americanbankingnews.comVicki Sato Sells 22,000 Shares of Vir Biotechnology (NASDAQ:VIR) StockMay 5 at 4:52 AM | insidertrades.comVir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 SharesMay 4 at 2:51 PM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 3 at 4:19 AM | marketbeat.comWhy Vir Biotechnology (VIR) Is Down 5.1% After Astellas Oncology Deal And Brii ArbitrationApril 29, 2026 | finance.yahoo.comVir Biotechnology (VIR) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?April 27, 2026 | finance.yahoo.comVir Biotechnology to Host Conference Call for First Quarter 2026 Financial ResultsApril 23, 2026 | businesswire.comVir Biotechnology Marks Key Hepatitis B Milestone With Phase 2 Combo Study UpdateApril 23, 2026 | tipranks.com10 Best Small-Cap Biotech Stocks According to Hedge FundsApril 21, 2026 | insidermonkey.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - Here's WhyApril 20, 2026 | marketbeat.comCan Vir Biotechnology (VIR)’s Masked T-Cell Technology Crack the Hardest-to-Treat Prostate Cancer?April 20, 2026 | insidermonkey.comIs Vir Biotechnology (VIR) One of the Best Low Priced Biotech Stocks to Invest In?April 19, 2026 | finance.yahoo.comVir Biotechnology, Inc. ($VIR) CEO 2025 Pay RevealedApril 16, 2026 | quiverquant.comQVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate CancerApril 16, 2026 | businesswire.comVir Biotechnology Rings the Closing BellApril 14, 2026 | nasdaq.comA Look At Vir Biotechnology (VIR) Valuation After New VIR-5500 Prostate Cancer Trial MilestoneApril 14, 2026 | finance.yahoo.comVir Biotechnology doses first patient in Phase I VIR-5500 trialApril 14, 2026 | yahoo.comVir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with ...April 13, 2026 | finance.yahoo.comFirst Patient Dosed in VIR-5500 T-Cell Engager Trial in Metastatic Prostate CancerApril 13, 2026 | targetedonc.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAI, Satellites and Staples: Insiders Are Buying and Selling 3 Big NamesBy Leo Miller | April 13, 20265 Space Stocks Already Climbing Ahead of the SpaceX IPOBy Bridget Bennett | April 14, 2026A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson | April 7, 2026Meta Platforms Earnings Preview: What to Watch in Q1 2026 ReportBy Leo Miller | April 27, 2026Going Dark: A Strange Buy Signal from the StarsBy Jeffrey Neal Johnson | April 8, 2026CTX, HEXO, LABS, and VIR Company DescriptionsCrescita Therapeutics TSE:CTXC$0.76 0.00 (0.00%) As of 12:35 PM EasternCrescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue.HEXO TSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.MediPharm Labs TSE:LABSC$0.08 0.00 (0.00%) As of 03:53 PM EasternFounded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products produced in a GMP-certified facility with ISO-standard clean rooms. MediPharm has invested in an expert research-driven team, state-of-the-art technology, advanced purification methodologies, and purpose-built facilities to deliver pure, trusted, precision-dosed cannabinoid products for domestic and international markets.Vir Biotechnology NASDAQ:VIR$10.01 -0.17 (-1.67%) Closing price 04:00 PM EasternExtended Trading$10.20 +0.20 (+1.95%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
